MARKET

ZYME

ZYME

Zymeworks
NYSE

Real-time Quotes | Nasdaq Last Sale

34.04
+0.26
+0.76%
Opening 12:12 04/02 EDT
OPEN
34.29
PREV CLOSE
33.78
HIGH
35.22
LOW
33.69
VOLUME
115.62K
TURNOVER
--
52 WEEK HIGH
52.75
52 WEEK LOW
14.65
MARKET CAP
1.55B
P/E (TTM)
-9.2807
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZYME stock price target is 52.91 with a high estimate of 70.00 and a low estimate of 25.00.

EPS

ZYME News

More
  • Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
  • Business Wire · 18h ago
  • Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
  • Business Wire · 03/16 11:50
  • Zymeworks (ZYME) Presents At Raymond James Institutional Investors Conference - Slideshow
  • Seeking Alpha - Article · 03/04 20:28
  • H.C. Wainwright Reiterates Buy on Zymeworks, Lowers Price Target to $60
  • Benzinga · 03/03 18:14

Industry

Biotechnology & Medical Research
+2.45%
Pharmaceuticals & Medical Research
+1.88%

Hot Stocks

Symbol
Price
%Change

About ZYME

Zymeworks Inc is a Canada-based biopharmaceutical company. The Company specializes in the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The Company operates through a number of platforms, including Azymetric platform, which is developed for the development of IgG-like, novel bispecific antibodies for the targeting of synergistic drug targets; Albucore platform, which is developed as a flexible and alternative platform to antibodies where it is advantageous for multi-valent therapeutic to target multiple disease targets; Effect, which comprises a library of Fc modifications that can selectively modulate the activity of recruited immune cells, and the ZymeLink Conjugation platform, which is a suite of novel protein site-specific conjugation technologies and customizable cleavable and non-cleavable linkers that is compatible with a variety of small molecule therapeutics.
More

Webull offers kinds of Zymeworks Inc stock information, including NYSE:ZYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYME stock news, and many more online research tools to help you make informed decisions.